126
|
Loret C, Walter M, Pineau N, Peyron M, Hartmann C, Martin N. Physical and related sensory properties of a swallowable bolus. Physiol Behav 2011; 104:855-64. [DOI: 10.1016/j.physbeh.2011.05.014] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2010] [Revised: 05/06/2011] [Accepted: 05/10/2011] [Indexed: 11/26/2022]
|
127
|
Bobzin K, Bagcivan N, Ewering M, Gillner A, Beckemper S, Hartmann C, Theiss S. Nano structured physical vapor deposited coatings by means of picosecond laser radiation. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY 2011; 11:8775-8781. [PMID: 22400258 DOI: 10.1166/jnn.2011.3468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Molding of nano structures by injection molding leads to special requirements for the tools e.g., wear resistance and as low as possible release forces of the molded components. On the other hand it is not allowed to affect the replication precision. Physical vapor deposition is one of the promising technologies for applying coatings with adapted properties like high hardness, low roughness, low Young's modulus and less adhesion to the plastics melt. Although physical vapor deposition technology allows the deposition of films on micro structures without changing the structure significantly, film deposition on nano structures and small micro structures leads to a relevant change in surface topography. For this reason direct structuring of physical vapor deposition coatings might be beneficial. In this paper structuring was done using a picoseconds ultraviolet laser, Lumera Laser "Rapid," with a master oscillator power amplifier system at 355 nm. Two different coatings were deposited by magnetron sputter ion plating physical vapor deposition technology for laser structuring tests ((Cr, Al)N, (Cr, Al,Si)N). After deposition, the coatings were analyzed by common techniques regarding hardness, Young's modulus and morphology. The structures were analyzed by scanning electron microscopy. The results show a high potential for laser structuring of coatings deposited via physical vapor deposition. Linear structures with sizes between 400 nm and 10microm were realized.
Collapse
|
128
|
Hartmann C, Schuchmann M, Zimmermann T. Posttransplant lymphoproliferative disease in liver transplant patients. Curr Infect Dis Rep 2011; 13:53-9. [PMID: 21308455 DOI: 10.1007/s11908-010-0145-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Posttransplant lymphoproliferative disorders (PTLD) are a life-threatening complication following solid organ transplantation. Many posttransplant lymphomas develop from the uncontrolled proliferation of Epstein-Barr virus (EBV)-infected B-cells, whereas EBV-negative PTLDs were increasingly recognized within the past decade. Major risk factors for the development of PTLDs after liver transplantation are immunosuppressive therapy and the type of underlying disease: viral hepatitis, autoimmune liver disease, or alcoholic liver cirrhosis contribute to an increased risk for PTLD. Therapeutic regimens include reduction of immunosuppression, the anti-CD20 antibody rituximab, and chemotherapy, as well as new approaches using interferon-α and anti-interleukin-6 antibodies. Despite the different therapeutic regimens, mortality from PTLD remains high. Therefore, it is of major importance to identify patients at risk at an early stage of the disease. In this review, risk factors for PTLD development after liver transplantation, clinical presentation, diagnosis, and therapy are discussed.
Collapse
|
129
|
Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A. Scientific correspondence. Neuropathol Appl Neurobiol 2011; 37:428-30. [DOI: 10.1111/j.1365-2990.2010.01127.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
130
|
Wick W, Steinbach J, Combs SE, Platten M, Hartmann C, Wenz FK, Boecker U, Stoffregen C. Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
131
|
Elsir T, Qu M, Berntsson SG, Orrego A, Olofsson T, Lindström MS, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A. PROX1 is a predictor of survival for gliomas WHO grade II. Br J Cancer 2011; 104:1747-54. [PMID: 21559010 PMCID: PMC3111172 DOI: 10.1038/bjc.2011.162] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Background: The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in individual patients is of great clinical value. PROX1 is a transcription factor that has a critical role in the development of various organs. PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers. We have recently shown that PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in grade II gliomas. Methods: A total of 116 samples were evaluated for the presence of PROX1 protein. The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group. Results: Higher PROX1 protein was associated with poor outcome. In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours. Conclusion: PROX1 is a novel predictor of survival for grade II gliomas.
Collapse
|
132
|
Radbruch A, Wiestler B, Bäumer P, Kramp L, Stieltjes B, Boppel T, Lutz K, Hartmann C, Wick W, Heiland S, Bendszus M. Abgrenzung von höher- und niedrigmalignen Astrozytomen mittels Suszeptibilitäts-gewichteter-Bildgebung. ROFO-FORTSCHR RONTG 2011. [DOI: 10.1055/s-0031-1279166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
133
|
Brehmer S, Pusch S, Schmieder K, von Deimling A, Hartmann C. Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Neuropathol Appl Neurobiol 2011; 37:330-2. [DOI: 10.1111/j.1365-2990.2010.01114.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
134
|
Prada J, Schruender S, Ngo-Tu T, Baatz H, Hartmann C, Pleyer U. Expression of tumor necrosis factor-α and interleukin-6 in corneal cells after excimer laser ablation in Wistar rats. Eye (Lond) 2011; 25:534-6. [PMID: 21293497 DOI: 10.1038/eye.2011.6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
135
|
Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Pöpperl G, Kreth FW. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011; 13:307-16. [PMID: 21292686 DOI: 10.1093/neuonc/noq196] [Citation(s) in RCA: 170] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Molecular imaging studies have recently found inter- and intratumoral heterogeneity in World Health Organization (WHO) grade II gliomas. A correlative analysis with tumor histology, however, is still lacking. For elucidation we conducted the current prospective study. Fifty-five adult patients with an MRI-based suspicion of a WHO grade II glioma were included. [F-18]Fluoroethyltyrosine ((18)FET) uptake kinetic studies were combined with frame-based stereotactic localization techniques and used as a guide for stepwise (1-mm steps) histopathological evaluation throughout the tumor space. In tumors with heterogeneous PET findings, the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and expression of mutated protein isocitrate dehydrogenase variant R132H (IDH1) were determined inside and outside of hot spot volumes. Metabolic imaging revealed 3 subgroups: the homogeneous WHO grade II glioma group (30 patients), the homogeneous malignant glioma group (10 patients), and the heterogeneous group exhibiting both low- and high-grade characteristics at different sites (15 patients). Stepwise evaluation of 373 biopsy samples indicated a strong correlation with analyses of uptake kinetics (p < 0.0001). A homogeneous pattern of uptake kinetics was linked to homogeneous histopathological findings, whereas a heterogeneous pattern was associated with histopathological heterogeneity; hot spots exhibiting malignant glioma characteristics covered 4-44% of the entire tumor volumes. Both MGMT and IDH1 status were identical at different tumor sites and not influenced by heterogeneity. Maps of (18)FET uptake kinetics strongly correlated with histopathology in suspected grade II gliomas. Anaplastic foci can be accurately identified, and this finding has implications for prognostic evaluation and treatment planning.
Collapse
|
136
|
Bertelmann E, Hartmann C, Minko N. Intraorbitale kavernöse Hämangiome: Symptomatik, Diagnostik und operative Zugänge. Klin Monbl Augenheilkd 2011; 228:49-53. [DOI: 10.1055/s-0029-1245961] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
137
|
Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010; 29:4517-27. [PMID: 20514015 DOI: 10.1038/onc.2010.195] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Aberrant activation of the epidermal growth factor receptor (EGFR) has been found in human cancers of various origins, and has been implicated in cancer pathogenesis. The therapeutic anti-EGFR antibodies cetuximab and matuzumab inhibit both ligand-induced receptor activation and growth of EGFR-expressing tumor cells. The efficacy of such EGFR-targeted therapies may be further enhanced by induction of functionally equivalent endogenous antibody responses. Here we describe novel peptide sequences selected from random peptide libraries for binding to single-chain antibody fragments of cetuximab or matuzumab. Two of these peptides characterized by KTL and YPLG motifs are recognized equally well by cetuximab and matuzumab, although nonoverlapping epitopes were previously reported for these antibodies. Immunization of experimental animals with synthetic KTL- and YPLG-containing peptides led to induction of antibodies that cross-react with human EGFR, and prevent binding of natural EGFR ligands, ligand-induced receptor activation and tumor cell growth in a manner similar to cetuximab and matuzumab. Our findings show that these peptide mimotopes can induce anti-EGFR antibodies with antitumoral activity, which may have implications for EGFR-specific cancer immunotherapy.
Collapse
|
138
|
Combs SE, von Deimling A, Debus J, Schulz-Ertner D, Hartmann C. High-dose radiation therapy using photons and carbon ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using of carbon ion radiotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
139
|
Hartmann C, Peter C, Hermann E, Ure B, Hansen G, Bohnhorst B. Vancomycin-resistente Enterococcus faecium Ventrikulitis bei spinal disseminiertem Sacrococcygealteratom: erfolgreiche i.v. und i.th. Chloramphenicol-Therapie. Z Geburtshilfe Neonatol 2010. [DOI: 10.1055/s-0030-1248818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
140
|
Combs S, Schulz-Ertner D, von Deimling A, Debus J, Hartmann C. Impact of the New WHO Classification on Decision-making for Radiation Therapy in Patients with Atypical and Anaplastic Meningiomas. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.309] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
141
|
Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, Reifenberger G, Lichter P, Herold-Mende C, Radlwimmer B. Genomic and Expression Profiling of Glioblastoma Stem Cell-Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival. Clin Cancer Res 2009; 15:6541-50. [DOI: 10.1158/1078-0432.ccr-09-0695] [Citation(s) in RCA: 130] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
142
|
Wick A, Dörner N, Heiland S, Hartmann C, Platten M, Bendszus M, Wick W. MRT Verlaufsuntersuchungen unter Bevacizumab: Bedeutung von MGMT? AKTUELLE NEUROLOGIE 2009. [DOI: 10.1055/s-0029-1238503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
143
|
Combs SE, Hartmann C, Welzel J, von Deimling A, Debus J, Platten M, Wick W, Gaiser T. Influence of expression of EGFR and PTEN on outcome in patients with primary glioblastoma treated with standard radiochemotherapy and cetuximab: Interim analysis from the GERT-Protocol. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2050 Background: The epidermal growth factor receptor (EGFR) is commonly amplified, overexpressed, and mutated in glioblastoma (GBM). Anti-EGFR treatments have shown to be associated with EGFR deletion mutant variant III (EGFRvIII) expression in presence of PTEN expression, suggesting a prognostic role of EGFRvIII expression. We determined molecular biomarkers and correlated these with outcome in the GERT trial. Methods: To date, 39 patients were treated within the GERT protocol (Combs SE et al., 2006) evaluating radiochemotherapy (RCHT) with temozolomide (TMZ) and weekly CTX. Pretreatment paraffin-embedded tumor tissue of 32 patients was available for molecular analysis. Twenty-three patients were male, 9 were female. Median age was 49 years. We analyzed amplification of EGFR, expression of EGFR, EGFRvIII, the tumor-suppressor PTEN and O(6)-methylguanine DNA methyltransferase (MGMT) gene promoter methylation. Results: Median follow-up was 12 months. Overall survival (OS) at 12 and 24 months was 89% and 42%. Progression-free survival (PFS) was 76% and 45% at 6 and 12 months, respectively. MGMT promoter hypermethylation was detected in 16/32 tumours. Methylated MGMT did not impact PFS or OS (p = 0.48 and p = 0.08). Data on EGFR copy number of 31/32 tumors showed EGFR gene amplification in 11 tumors. EGFR protein expression was found in 23/32 patients. EGFR-amplification did not impact PFS or OS (p = 0.56, p = 0.3). Patients with EGFR expression showed longer PFS (p = 0.05), but unaltered OS (p = 0.06). EGFRvIII was seen in 5/32 patients, only in tumors with EGFR amplification. Expression of EGFRvIII did not influence PFS (p = 0.26) or OS (p = 0.09). Reduced PTEN (22/32) did not influence PFS or OS (p = 0.27, p = 0.85). Outcome was not associated with coexpression of EGFRvIII and PTEN (n = 5); coexpression of EGFR and PTEN (n = 13) significantly influenced PFS (p = 0.005), but not OS (p = 0.10). Conclusions: Expression of EGFR, and coexpression of EGFR/PTEN is associated with significant increase in PFS after RCHT with TMZ and CTX. EGFR-amplification, reduction of PTEN expression and expression of EGFRvIII did not impact PFS nor OS. Randomized data in the primary treatment of GBM might help identify patients for anti-EGFR therapies. [Table: see text]
Collapse
|
144
|
Andrieu S, Barberger-Gateau P, Raffaitin C, Berr C, Tzourio C, Dartigues JF, Gin H, Fitten LJ, Ortiz F, Fairbanks L, Bartzokis G, Lu P, Ringman J, Heyn PC, Locher JL, Salvà A, Andrieu S, Fernández E, Vellas B, van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Beekman ATF, Hoefnagels WHL, de Groot CPGM, Angevaren M, Aufdemkampe G, Verhaar HJJ, Aleman A, Vannees L, Arkin S, Florez H, Gerstein H, Sheridan P, Bosch J, Goldberg R, Kaspar KM, Drawert SM, Marcus RL, Kidde J, Dibble L, Addison O, LaStayo PC, Scarmeas N, Stern Y, Schupf N, Luchsinger JA, Sharkey JR, Laditka JN, Laditka SB, Liu R, Hochhalter A, Robare JF, Türner N, Judge M, Foster TC, Erdos B, Cudykier I, Scarpace PJ, Weiss LA, Bergstrom J, Kritz-Silverstein D, Barrett-Connor E, Yurko-Mauro K, Nelson E, Quinn J, Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Hahn C, Colletti P, Roubenoff R, Yarasheski KE, Azen SP, Aoki Y, Yamamoto T, Otuka T, Blanc-Bisson C, Bourdel-Marchasson I, Bocock MA, Keller HH, Bowman G, Baxter J, Oken B, Frei B, Traber M, Leonard S, Kaye J, Shannon J, Quinn J, Carlsson M, Gustafson Y, Eriksson S, Littbrand H, Håglin L, Danthiir V, Wilson C, Nettelbeck T, Burns N, Wittert G, Noakes M, Clifton P, DiMaria-Ghalili RA, Grieger JA, Nowson CA, Wattanapenpaiboon NT, Holstein J, Robinson C, Hartmann C, Rueb S, Heffel L, Dintaman S, Reynolds J, Fleming L, Crull M, Goldey J, Serper LL, Hubbard R, Westengard J, Horning M, Ishige Y, Aoki Y, Keller HH, Keller HH, LaStayo PC, Marcus RL, Smith S, Kidde J, Dibble L, Butler C, Hill M, LaStayo PC, Marcus RL, Dibble L, Kidde J, Peters C, Meier W, Laughlin GA, Kritz-Silverstein D, von Muhlen D, Barrett-Connor E, Olariu L, Petcu M, Tulcan C, Pup M, Otilingam P, Gate M, Pasinetti GM, Ray B, Chauhan NB, Bailey JA, Lahiri DK, Shatenstein B, Kergoat MJ, Reid I, Chicoine ME, Vaz L, Stewart R, Sabbah W, Tsakos G, D’Aiuto F, Watt RG, Sturman M, Kelly J, Fleischman D, Leurgans S, Bennett D, Morris MC, Suominen MH, Muurinen S, Soini H, Pitkälä KH, Yamamoto T, Fujinoki C, Aoki Y. 3rd IANA (International Academy on Nutrition and Aging) Meeting Nutrition, Exercise & Alzheimer and Clinical Trials on Sarcopenia August 1–2, 2008 Hyatt Regency Tamaya Resort 1300 Tuyuna Trail Santa Ana Pueblo, NM USA. J Nutr Health Aging 2008. [DOI: 10.1007/bf02982702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
145
|
Combs S, Schulz-Ertner D, Hartmann C, Welzel T, Timke C, Herfarth K, von Deimling A, Platten M, Wick W, Debus J. Erbitux® (Cetuximab) Plus Temozolomide as Radiochemotherapy for Primary Glioblastoma (GERT): Interim Results of a Phase I/II Study. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.790] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
146
|
Grauer O, Hartmann C, Proescholdt M, Pascher C, Hirschmann B, Brawanski A, Pietsch T, Bogdahn U, Hau P. Neoadjuvante Chemotherapie mit Temozolomid und 13-cis Retinsäure in der Therapie von Patienten mit anaplastischen astrozytären und oligoastrozytären Tumoren (WHO Grad III) – eine Phase-II-Studie. AKTUELLE NEUROLOGIE 2008. [DOI: 10.1055/s-0028-1086673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
147
|
Schurr MO, Hartmann C, Ho CN, Fleisch C, Kirschniak A. An over-the-scope clip (OTSC) system for closure of iatrogenic colon perforations: results of an experimental survival study in pigs. Endoscopy 2008; 40:584-8. [PMID: 18521795 DOI: 10.1055/s-2008-1077354] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND STUDY AIM Perforation of the colon is a relatively rare complication of flexible endoscopy of the lower gastrointestinal tract. It has a reported incidence from between 0.2 % in diagnostic procedures to 0.5 % - 3 % in therapeutic procedures. Given the growing number of colonoscopies, the absolute number of iatrogenic perforations is not unimportant. The treatment of choice is most often surgical repair, since reliable and simple endoscopic techniques for perforation closure are currently unavailable. We aimed to evaluate our novel over-the-scope clip (OTSC) system for closure of iatrogenic perforations. MATERIAL AND METHODS We have developed a nitinol clip that will capture perforations of 10 - 15 mm, compressing the lesions until healing. The OTSC was studied in a prospective experimental trial in pigs (50 - 60 kg, n=10) for the closure of an iatrogenic perforation of approximately 5 --10 mm on the serosal side, that was created by repeated endoscopic biopsy. The follow-up period was 12 weeks. Follow-up colonoscopy was performed at 4 and 12 weeks. Successful, tight closure of the lesion with absence of peritonitis in the postoperative course was the primary endpoint of the study. RESULTS Nine animals had an uneventful clinical course. At termination of the study, macroscopic and microscopic examination of the clipping sites in the bowel wall showed normal tissue healing. One animal died 1 day postoperatively for reasons unrelated to the procedure. CONCLUSIONS In this experimental study the OTSC clip system was found to be a simple and secure closure method for iatrogenic colon perforations, and thus might be an alternative to surgical repair.
Collapse
|
148
|
Chen XF, Siche D, Albrecht M, Hartmann C, Wollweber J, Xu XG. Surface preparation of AlN substrates. CRYSTAL RESEARCH AND TECHNOLOGY 2008. [DOI: 10.1002/crat.200800057] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
149
|
Combs SE, Schulz-Ertner D, Hartmann C, Welzel T, Timke C, Herfarth K, von Deimling A, Edler L, Platten M, Wick W, Debus J. Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)—Eudract number 2005–003911–63; NCT00311857. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2077] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
150
|
Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Schuth J, Bamberg M, von Deimling A, Weller M, Wick W. Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|